Business Context and Reporting Period
This Form 6-K filing by Kamada Ltd. (NASDAQ & TASE: KMDA) covers the month of July 2018, with the report dated July 26, 2018. Kamada is a plasma-derived protein therapeutics company headquartered in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event disclosure rather than a financial statement.
Material Changes and Events
- Labor Strike: On July 22, 2018, the Employees' Committee at Kamada's Beit Kama production facility in Israel commenced a labor strike.
- Cause: The strike resulted from ongoing negotiations to renew a collective bargaining agreement with the Histadrut (General Federation of Labor in Israel) and the Employees' Committee, which expired on December 31, 2017.
- Scope: The work stoppage involves only plant labor. Research and development (R&D) and clinical development activities are not impacted.
Outlook, Risks, and Management Commentary
- Financial Impact: Management states it cannot predict the duration of the strike or whether it will have a material direct effect on financial results. However, the Company does not currently anticipate a materially adverse impact on its financial condition or product supply.
- Risk Factors: The filing references risks associated with labor disputes, potential work stoppages, and increased labor costs as detailed in the Company's Form 20-F for the period ended December 31, 2017.
- Forward-Looking Statements: The report includes forward-looking statements regarding the timing of the strike resolution and its business impact, which are subject to uncertainties and may differ materially from actual results.
Key Facts for Investor Verification
- Verify the duration of the strike and any subsequent updates on the collective bargaining agreement negotiations.
- Monitor future filings for any material adverse effects on production capacity or product supply chains.
- Review the Company's Form 20-F for the period ended December 31, 2017, for detailed risk factors regarding labor relations.
- Confirm that R&D and clinical trial timelines remain unaffected by the production facility work stoppage.